Don’t Miss TipRanks’ Half-Year Sale
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
- Make smarter investment decisions with TipRanks' Smart Investor Picks, delivered to your inbox every week.
Galenica AG ( (CH:GALE) ) just unveiled an announcement.
Galenica AG has announced its entry into the diagnostics business through the acquisition of Labor Team Group, a leading Swiss diagnostics service provider. This strategic move is expected to strengthen Galenica’s healthcare network and expand its offerings in the medical segment, particularly in diagnostics. The acquisition aligns with Galenica’s goal of enhancing healthcare connectivity and innovation, and it positions the company to meet future regulatory challenges in the Swiss laboratory market. The transaction is subject to approval by the Swiss Competition Commission and is anticipated to close in the second half of 2025.
The most recent analyst rating on (CH:GALE) stock is a Hold with a CHF89.00 price target. To see the full list of analyst forecasts on Galenica AG stock, see the CH:GALE Stock Forecast page.
More about Galenica AG
Galenica AG is a prominent player in the Swiss healthcare market, offering a range of services including pharmacies, pharmaceutical logistics, and home care. The company is committed to enhancing the health and well-being of people in Switzerland and is listed on the Swiss stock exchange. Galenica aims to shape the future of healthcare by leveraging its extensive network and expertise.
Average Trading Volume: 108,835
Current Market Cap: CHF4.27B
Find detailed analytics on GALE stock on TipRanks’ Stock Analysis page.